Related Experiment Video

Updated: May 16, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary

Joerg Herrmann1, Ryan J Lennon, Gregory W Barsness

  • 1Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Circulation. Cardiovascular Interventions
|December 6, 2012
PubMed

Insights

High sensitivity C-reactive protein (hsCRP) predicts periprocedural myocardial infarction but not long-term mortality after percutaneous coronary intervention. Routine hsCRP measurement is unlikely to benefit patients undergoing PCI.

Area of Science:

  • Cardiology
  • Biomarkers
  • Interventional Cardiology

Background:

  • High sensitivity C-reactive protein (hsCRP) is a known predictor of cardiovascular events.
  • Its role in risk stratification for contemporary percutaneous coronary intervention (PCI) is not well-established.

Purpose of the Study:

  • To investigate the association between hsCRP levels and outcomes in patients undergoing PCI.
  • To determine if hsCRP can predict periprocedural myocardial infarction and long-term mortality.

Main Methods:

  • Prospective study of 513 patients undergoing non-emergency PCI.
  • Analysis of pre- and postprocedural hsCRP levels in relation to clinical outcomes.
  • Follow-up for 5-year mortality and composite endpoints.

Main Results:

  • Elevated preprocedural hsCRP was an independent predictor of periprocedural myocardial infarction (OR 1.15 per doubling).
  • Unadjusted 5-year mortality and death/MI composite endpoint were higher in patients with high hsCRP.
  • Neither pre- nor postprocedural hsCRP independently predicted mortality after multivariable adjustment.

Conclusions:

  • High hsCRP is linked to increased risk of periprocedural myocardial infarction but not long-term mortality post-PCI.
  • Routine hsCRP measurement in PCI patients is unlikely to be beneficial in current practice.
Abstract

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...